Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting c-myc in leukemia

B Calabretta1, T Skorski

  • 1Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Anti-Cancer Drug Design
|July 1, 1997
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia.

Leukemia·2016
Same author

Expression of μ-protocadherin is negatively regulated by the activation of the β-catenin signaling pathway in normal and cancer colorectal enterocytes.

Cell death & disease·2016
Same author

CDKN2A-independent role of BMI1 in promoting growth and survival of Ph+ acute lymphoblastic leukemia.

Leukemia·2016
Same author

AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.

Leukemia·2014
Same author

Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.

Leukemia·2013
Same author

BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.

Leukemia·2012
Same journal

Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

Anti-cancer drug design·2002
Same journal

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

Anti-cancer drug design·2002
Same journal

The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?

Anti-cancer drug design·2002
Same journal

Photokilling of cultured tumour cells by the porphyrin derivative CF3.

Anti-cancer drug design·2002
Same journal

Cyclohexylamino-demethoxy-hypocrellin B and photodynamic therapy decreases human cancer in vitro.

Anti-cancer drug design·2002
Same journal

Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues.

Anti-cancer drug design·2002
See all related articles